Pre-Open 12/04: (HQY) (CHK) (EXPE) Higher (RVNC) (IMMU) (ZS) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Revance Therapeutics (RVNC) Reports Publication of Pooled Results from Phase 3 Trials for Glabellar Lines
December 5, 2019 8:02 AM ESTRevance Therapeutics, Inc. (NASDAQ: RVNC) today announced the publication of the pooled data from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies (SAKURA 1 and SAKURA 2) evaluating Revances long-acting neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI) for the treatment of moderate to severe glabellar (frown)... More
Immunomedics (IMMU) Prices 14.286M Share Common Offering at $17.50/Sh
December 5, 2019 5:51 AM ESTImmunomedics, Inc. (NASDAQ: IMMU) today announced the pricing of an... More
Piper Jaffray Sees Expedia (EXPE) in 'Holding Period' Amid CEO/CFO Exit
December 4, 2019 10:15 AM ESTPiper Jaffray analyst Michael Olson weighed in on Expedia (NASDAQ: EXPE) after the CEO and CFO both left amid a disagreement with the Board. The analyst said the management changes suggests the stock will remain in a multi-quarter holding period.
The reiterated a... More
